首页> 外文期刊>Progress in respiratory research >Anti-Inflammatory AgentsA Clinical Perspective
【24h】

Anti-Inflammatory AgentsA Clinical Perspective

机译:抗炎药的临床前景

获取原文
获取原文并翻译 | 示例
       

摘要

Neutrophil-dominated airway inflammation begins early in cystic fibrosis (CF) and is integral to progressive lung damage. It is, therefore, logical to attempt to modify this inflammatory response, ideally as early as possible, and before sustained severe inflammation is established. Oral corticosteroids have been shown to slow the progression of lung disease, but have unacceptable side effects for long-term use. Inhaled corticosteroids, although widely prescribed, have not been shown to be an effective anti-inflammatory agent in CF, and they may not be as safe as previously assumed. High-dose oral ibupro-fen has proven efficacy, but its potential adverse effects have limited its uptake in clinical practice. Antileukotrienes have had limited study in CF, but as yet no significant benefit has been demonstrated. There were encouraging early phase trials of aerosolized antiproteases but they have not been developed further, and the focus is now on novel synthetic anti-elastase agents. Nebulized recombinantDNase, despite concerns of a possible pro-inflammatory effect, in fact appears to stabilize airway inflammation in mild lung disease. Macro-lide antibiotics have been shown to have a small but significant beneficial effect on pulmonary function, and although the mechanism is unclear, it is likely that it relates to an anti-inflammatory effect. Other anti-inflammatory therapies that have been tried in difficult asthma, e.g. cyclosporine, metho-trexate and intravenous immunoglobulin, have had very limited study, and their effect in CF is unproven. Finally, there are a number of novel agents, which target individual inflammatory mediators and pathways, which are being studied in thelaboratory setting. Although it is quite likely their actions are too specific to cope with the generalized inflammatory response in CF, there is hope that an agent will be found that significantly limits inflammation, but that also has an acceptable side-effect profile and a suitable route of delivery.
机译:中性粒细胞为主的气道炎症在囊性纤维化(CF)的早期开始,是进行性肺损伤不可或缺的部分。因此,在理想的情况下尽早且在建立持续的严重炎症之前尝试改变这种炎症反应是合乎逻辑的。口服皮质类固醇已被证明可减慢肺部疾病的进展,但长期使用具有不可接受的副作用。吸入皮质类固醇虽然被广泛开具处方,但尚未显示出可作为CF中有效的抗炎药,并且它们可能不如先前假定的安全。大剂量口服布洛芬已被证明具有疗效,但其潜在的不良反应限制了其在临床实践中的吸收。抗白三烯在CF中的研究有限,但尚未显示出明显的益处。雾化抗蛋白酶的早期试验令人鼓舞,但尚未得到进一步开发,现在的重点是新型合成抗弹性蛋白酶剂。尽管担心可能的促炎作用,但雾化的重组DNase实际上似乎可以在轻度肺部疾病中稳定气道炎症。大环内酯类抗生素已显示出对肺功能的作用很小但很明显,尽管其作用机理尚不清楚,但很可能与抗炎作用有关。在困难的哮喘中尝试过的其他抗炎疗法,例如环孢霉素,甲氨蝶呤和静脉注射免疫球蛋白的研究非常有限,其在CF中的作用尚未得到证实。最后,有许多针对个体炎症介质和途径的新型药物正在实验室中进行研究。尽管它们的作用很可能太过特殊而无法应对CF中的全身性炎症反应,但还是希望能找到一种能显着限制炎症但又具有可接受的副作用和合适的给药途径的药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号